Project Grant 2337317
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Awardee
Genexgen Inc. (JY3VPNHXH8D7)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...
This $305,000 Small Business Innovation Research (SBIR) Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a new class of gene therapies delivered more safely, cost-effectively, and at scale for serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes,...
Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This Project Grant award of $304,951 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a scalable and cost-effective manufacturing process for extracellular vesicle (EV)-based gene therapy delivery systems at Neucore Bio, Inc. The project aims to address key technical challenges in EV isolation, purification, and cargo loading to enhance the therapeutic efficacy of EV-based gene therapies, particularly...
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
This Project Grant award of $450,000 from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports the development of biosensors to quantify the genetic payload of viral vectors used in gene therapy. The project aims to create a novel biosensing technology that can differentiate between functional viral vectors and defective particles. This involves studying ligand interactions with full and empty viruses, integrating the ligands with electrochemical biosensors, and...
The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...